JP2024511611A5 - - Google Patents

Info

Publication number
JP2024511611A5
JP2024511611A5 JP2023558350A JP2023558350A JP2024511611A5 JP 2024511611 A5 JP2024511611 A5 JP 2024511611A5 JP 2023558350 A JP2023558350 A JP 2023558350A JP 2023558350 A JP2023558350 A JP 2023558350A JP 2024511611 A5 JP2024511611 A5 JP 2024511611A5
Authority
JP
Japan
Prior art keywords
methyl
carbonyl
decane
azaspiro
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511611A (ja
Filing date
Publication date
Priority claimed from GBGB2104097.7A external-priority patent/GB202104097D0/en
Application filed filed Critical
Publication of JP2024511611A publication Critical patent/JP2024511611A/ja
Publication of JP2024511611A5 publication Critical patent/JP2024511611A5/ja
Pending legal-status Critical Current

Links

JP2023558350A 2021-03-24 2022-03-24 ユビキチン特異的プロテアーゼ１９阻害剤としての医薬化合物 Pending JP2024511611A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104097.7A GB202104097D0 (en) 2021-03-24 2021-03-24 Pharmaceutical compounds
GB2104097.7 2021-03-24
PCT/EP2022/057820 WO2022200523A1 (en) 2021-03-24 2022-03-24 Pharmaceuticals compounds as inhibitors of ubiquitin specific protease 19 (usp19)

Publications (2)

Publication Number Publication Date
JP2024511611A JP2024511611A (ja) 2024-03-14
JP2024511611A5 true JP2024511611A5 (enExample) 2025-03-26

Family

ID=75689814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558350A Pending JP2024511611A (ja) 2021-03-24 2022-03-24 ユビキチン特異的プロテアーゼ１９阻害剤としての医薬化合物

Country Status (12)

Country Link
US (1) US20240327382A1 (enExample)
EP (1) EP4313295A1 (enExample)
JP (1) JP2024511611A (enExample)
KR (1) KR20230160901A (enExample)
CN (1) CN117157285A (enExample)
AU (1) AU2022244178A1 (enExample)
BR (1) BR112023019323A2 (enExample)
CA (1) CA3212236A1 (enExample)
GB (1) GB202104097D0 (enExample)
IL (1) IL307163A (enExample)
MX (1) MX2023011012A (enExample)
WO (1) WO2022200523A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115656383A (zh) * 2022-11-11 2023-01-31 武汉海特生物创新医药研究有限公司 一种alpha-苯基哌啶-2-乙酰胺对映异构体的检测方法
GB202311227D0 (en) 2023-07-21 2023-09-06 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335701B1 (en) * 2003-12-15 2012-07-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
HK1248220A1 (zh) * 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
HK1248221A1 (zh) * 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
HK1248222A1 (zh) * 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂
GB201612938D0 (en) 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
US11465983B2 (en) * 2017-09-26 2022-10-11 Dana-Farber Cancer Institute, Inc. USP7 inhibitors for treating multiple myeloma
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
BR112021010645A2 (pt) * 2018-12-06 2021-08-17 Almac Discovery Limited composto, 1-(((s)-7-((r)-3-ciclohexil-2-metilpropanoil)-10-hidroxi-7-azaspiro[4.5]decan-10-il)metil)-4-fenil-5-(piperazina-1-carbonila)piridin-2(1h)-ona, composição farmacêutica, métodos para tratamento de obesidade, de resistência à insulina, de diabetes tipo ii, de atrofia muscular, de câncer e para reduzir perda de massa muscular, e, inibidor de usp19
CN113365696A (zh) * 2018-12-06 2021-09-07 阿尔麦克探索有限公司 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途
WO2020227365A1 (en) * 2019-05-06 2020-11-12 Integral Early Discovery, Inc. Inhibiting usp19

Similar Documents

Publication Publication Date Title
KR101985050B1 (ko) 피라진카르복사미드 화합물
JP6318238B2 (ja) スルファモイルピロールアミド誘導体およびｂ型肝炎を処置するための医薬品としてのその使用
RU2375352C2 (ru) Амидные производные
CN105555783B (zh) 包含杂芳族环‑苄基‑酰胺‑环核心的自分泌运动因子抑制剂
JP2019523266A5 (enExample)
IL295799A (en) Trophomyosin receptor kinase (trk) degradation compounds and methods of use
CN103476771B (zh) 用于治疗自身免疫炎症的IL17和IFN-γ抑制
JP2019069941A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
JP2023505258A5 (enExample)
EP2590981B1 (en) Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
JP2022534979A5 (enExample)
JP2007519754A5 (enExample)
RU2008138993A (ru) Производные хинолина
WO2014181287A1 (en) Heterocyclyl compounds and uses thereof
KR20140048235A (ko) 신규 트리플루오로메틸-옥사디아졸 유도체 및 질환의 치료에서의 그의 용도
JP2014505037A5 (enExample)
AU2012345557A1 (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
RU2014142328A (ru) Производные пиперидина в качестве агонистов gpr119
JP2023528073A (ja) Ｇｐｒ６５モジュレーターとしてのｎ－フェニルアミノカルボニル、ピリジノ－、ピリミジノ及びベンゾトロパン
CN111868040A (zh) 2,4-二氨基喹唑啉衍生物及其医学用途
JP2019530708A5 (enExample)
RU2020115915A (ru) Бициклические сульфоны и сульфоксиды и способы их применения
JP2015524825A5 (enExample)
JP2022510700A5 (enExample)
RU2013136906A (ru) Новые производные сульфамидпиперазина в качестве ингибиторов протеинтирозинкиназы и их фармацевтическое применение